At a glance
ClinicalIndex Comparison RecordPhase 3Not Yet Recruiting· 450 target
Drug / intervention
simmitinib +1 moredrug
Likely dose
simmitinib 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Simmitinib Versus Investigator's Choice of Chemotherapy for Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma : a Randomised, Open-label, Multicentre, Phase 3 Study
Shanghai Runshi Pharmaceutical Technology Co., Ltd·interventional·Posted Oct 24, 2024·Updated Oct 24, 2024
In Brief
A Phase 3 clinical trial evaluating simmitinib and investigator's choice of chemotherapy,include docetaxel or irinotecan. for Advanced Oesophageal Squamous Cell Carcinoma. Not yet recruiting, targeting 450 participants.
Detailed Summary
To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3Not Yet Recruiting
202520262027
First PostedOct 2024
Enrollment StartOct 2024
TodayJul 2026
Primary CompletionJan 2027
First PostedOct 24, 2024
Enrollment StartOct 31, 2024
Primary CompletionJan 30, 2027
TodayJul 1, 2026
Enrollment to primary: 2.2 yearsPosted 1.7 years agoPrimary completion in 7 months
Interventions
simmitinibdrug
simmitinib 6mg,QD ,3 weeks on 1 week off
investigator's choice of chemotherapy,include docetaxel or irinotecan.drug
docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks